EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF‐2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma

Yihao Zhu, Yajian Li, Xuwen Li, Yuan Yu, Lingpu Zhang, Hanchen Zhang, Can Chen, Dong Chen, Mingshuai Wang, Nianzeng Xing, Feiya Yang, Wahafu Wasilijiang und 1 weitere

Advanced Healthcare Materials · 2024-12 · 13 (32)

DOI: 10.1002/adhm.202402973 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 13.10.2024. Verfasst von Yihao Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and P…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Immunotherapy, Basic Helix-Loop-Helix Proteins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockers (ICBs) therapy stands as the first‐line treatment option for advanced renal cell carcinoma (RCC). However, its effectiveness is hindered by the immunosuppressive tumor microenvironment (TME). Sonodynamic therapy (SDT) generates tumor cell fragments that can prime the host's antitumor immunity. Nevertheless, the hypoxic microenvironment and upregulated autophagy following SDT often lead to cancer cell resistance. In response to these challenges, a hypoxia‐responsive polymer (Poly(4,4′‐azobisbenzenemethanol‐PMDA)‐mPEG 5k , P‐APm) encapsulating both a HIF‐2α inhibitor (belzutifan) and the ultrasonic sensitize (Chlorin e6, Ce6) is designed, to create the nanoparticle APm/Ce6/HIF. APm/Ce6/HIF combined with ultrasound (US) significantly suppresses tumor growth and activates antitumor immunity in vivo. Moreover, this treatment effectively transforms the immunosuppressive microenvironment from “immune‐cold” to “immune‐hot”, thereby enhancing the response to ICBs therapy. The findings indicate that APm/Ce6/HIF offers a synergistic approach combining targeted therapy with immunotherapy, providing new possibilities for treating RCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsImmunotherapyBasic Helix-Loop-Helix ProteinsAutophagyNanoparticlesTumor MicroenvironmentAnimalsHumansMiceCell Line, TumorMice, Inbred BALB CChlorophyllidesEndothelial PAS Domain-Containing Protein 1

Stichwörter der Autor:innen

HIF‐2αimmunotherapyrenal cell carcinomasonodynamic therapy

Substanzen

Basic Helix-Loop-Helix ProteinsChlorophyllidesEndothelial PAS Domain-Containing Protein 1

Autor:innen und Institutionen

  • Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Zhejiang, 310022, China.
  • Beijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China.
  • University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Guizhou, 563000, China.
  • Department of Urology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Shanxi, 030013, China.

ORCID-Profile: Xiongjun Ye

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Zhu, Y., Li, Y., Li, X., Yu, Y., Zhang, L., Zhang, H., Chen, C., Chen, D., Wang, M., Xing, N., Yang, F., Wasilijiang, W., & Ye, X. (2024). Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF‐2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma. Advanced Healthcare Materials, 13(32). https://doi.org/10.1002/adhm.202402973

Vancouver

Zhu Y, Li Y, Li X, Yu Y, Zhang L, Zhang H, et al. Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF‐2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma. Advanced Healthcare Materials. 2024;13(32). doi:10.1002/adhm.202402973

BibTeX
@article{Zhu2024,
  author = {Zhu, Yihao and Li, Yajian and Li, Xuwen and Yu, Yuan and Zhang, Lingpu and Zhang, Hanchen and Chen, Can and Chen, Dong and Wang, Mingshuai and Xing, Nianzeng and Yang, Feiya and Wasilijiang, Wahafu and Ye, Xiongjun},
  title = {Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF‐2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  volume = {13},
  number = {32},
  doi = {10.1002/adhm.202402973}
}
Kostenlos starten →